Penumbra, Inc. (NYSE: PEN) shares advanced 1.01% to close at USD 256.06, marking a daily change of +2.57 as trading volume approached the company’s average. This update outlines the latest stock movement, company profile, and financial data relevant to investors and market watchers.
Company Overview
Founded in 2004 and headquartered in Alameda, California, Penumbra, Inc. operates in the healthcare sector with a focus on medical devices. The company designs, develops, manufactures, and markets a broad portfolio of products. These include aspiration-based thrombectomy systems, neurovascular embolization coiling systems, neurosurgical aspiration tools, and immersive computer-based therapeutic technologies.
Its devices target conditions ranging from vascular obstructions to neurovascular lesions. Product lines such as Penumbra RED, JET, ACE, Penumbra ENGINE, Coil 400, and Indigo System are part of its core portfolio. The company sells directly and through distributors in the United States and internationally.
Stock Performance Analysis
On the latest trading day, PEN closed at USD 256.06, gaining 1.01385% over the session. This reflects a price increase of 2.57 from the prior close. The stock’s 52-week range spans from USD 190.08 to USD 310.00, showing variability over the period but placing the current price toward the upper-middle part of this band.
The market capitalization stands at approximately USD 9.99 billion. This figure represents the aggregate value of outstanding shares and signals Penumbra’s position in the mid-to-large cap category within its sector. The absence of dividends suggests reinvestment of earnings into operations and growth initiatives rather than direct shareholder payouts.
Trading volume reached 362,538 with an average daily volume of 461,567. This level of liquidity supports active trading and can help ensure tighter bid-ask spreads.
Market Position and Sector Context
Penumbra occupies a specialized niche within the medical devices industry. The healthcare sector has shown steady demand for high-quality neurovascular and vascular intervention tools. Such devices, especially in critical care categories, often enjoy defensive business characteristics due to consistent demand irrespective of economic cycles.
In the competitive landscape, innovation and regulatory approval timelines are central factors. Penumbra’s sustained development pipeline supports its competitive stance, while its global footprint aids in market diversification.
Governance and Leadership
Chief Executive Officer Adam Elsesser leads Penumbra with over two decades of sector experience. Under this leadership, the company has expanded product lines and invested in innovative therapeutic systems, including immersive rehabilitation tools. Governance structures and strategic oversight play a key role in maintaining operational efficiency and compliance with regulatory requirements.
Key Financial Data
- Price: USD 256.06
- Change: +2.57 (+1.01385%)
- 52-Week Range: USD 190.08 – USD 310.00
- Market Capitalization: USD 9,986,116,972
- Last Dividend: None
- Trading Volume: 362,538
- Average Volume: 461,567
- Exchange: New York Stock Exchange (NYSE)
- ISIN: US70975L1070
- CUSIP: 70975L107
- Sector: Healthcare
- Industry: Medical – Devices
- Employees: 4,500
These indicators provide insight into share liquidity, valuation scale, and yield policy. For stakeholders, the absence of a dividend aligns with growth-oriented capital allocation.
FAQ
- Does Penumbra, Inc. pay dividends?
No. The company has not declared a dividend, reflecting a focus on reinvestment. - Where is Penumbra, Inc. listed?
PEN is traded on the New York Stock Exchange. - How many people work at Penumbra?
The company employs approximately 4,500 full-time staff. - What is the ISIN code for Penumbra?
US70975L1070. - What is the company’s industry classification?
Medical – Devices within the healthcare sector.
Conclusion and Investor Implications
Penumbra, Inc. demonstrates consistent operational and market strength, backed by specialized product lines and global sales channels. The current share price gains reflect investor confidence amid steady trading activity. Extended range positioning suggests room for further movement based on market and sector trends.
Disclaimer
This article is for informational purposes only. It should not be construed as investment advice or an offer to buy or sell securities.
Official Source
For full information about the company, see the link below.
https://www.penumbrainc.com